Deucravacitinib maintains efficacy through 2 years in psoriasis
MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress. “Many of the drugs we use lose efficacy over time, but we now have 2-year data of deucravacitinib, and it is a completely flat line. Patients who did well continue to do just as well 2
Source: healio.com